Glotica Tablets 60 mg (Ticagrelor)

Adult dose

Do not use this medicine concomitantly with other ADP receptor inhibitors (ticlopidine, clopidogrel, prasugrel). Acute coronary syndrome: Administer an initial dose of 180mg, followed by 90mg twice daily. Treatment for 12 months is recommended unless discontinuation is clinically necessary. Patients taking this medicine should also receive a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated. In patients with acute coronary syndrome who are at increased risk of bleeding and have undergone percutaneous coronary intervention (PCI), monotherapy with this medicine (discontinuation of aspirin) may be considered after concomitant administration of this medicine and aspirin for 3 months. (See 3. Patients requiring careful administration.) Patients with a history of myocardial infarction (occurring at least 1 year previously) who are at high risk of thrombotic cardiovascular events: Administer 60mg twice daily. Patients taking this medicine should also receive a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated. Patients taking 90mg of this medicine or another ADP receptor inhibitor (ticlopidine, clopidogrel, prasugrel) during the first year after myocardial infarction may continue treatment with 60mg of this medicine. This medicine may also be initiated in patients within 2 years after myocardial infarction or within 1 year of discontinuing a previous ADP receptor inhibitor (ticlopidine, clopidogrel, prasugrel). The safety and efficacy of this medicine were evaluated at 3 years of follow-up. Patients with type 2 diabetes who have undergone percutaneous coronary intervention (PCI) for coronary artery disease: Administer 60mg twice daily. Patients taking this medicine should also receive a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated. For patients with acute coronary syndrome, refer to the corresponding dosage and administration. Data on the safety and efficacy of this medicine for treatment lasting more than 3 years are limited. Patients with acute ischemic stroke or high-risk transient ischemic attack: Administer an initial dose of 180mg, followed by 90mg twice daily for 30 days. Patients taking this medicine should also receive a maintenance dose of aspirin (75 - 100mg), unless specifically contraindicated. An initial loading dose of aspirin (300-325mg) is recommended for patients with acute ischemic stroke or high-risk transient ischemic attack. This medicine is administered orally and may be taken with or without food. For patients who have difficulty swallowing tablets, crush this medicine into a fine powder, disperse it in half a cup of water, and drink the mixture. Rinse the cup with another half cup of water and drink it. This mixture may also be administered through a nasogastric tube (CH8 or larger); it is important to flush the tube with water after administration. When switching from another antiplatelet agent to this medicine, start this medicine 24 hours after the last dose of the previous medicine. If a dose is missed, take only 1 tablet (the next scheduled dose) at the next scheduled dosing time. No dose adjustment is necessary in patients with renal impairment. No dose adjustment is necessary in patients with mild hepatic impairment. This medicine has not been studied in patients with severe hepatic impairment, and experience with its use in patients with moderate hepatic impairment is limited.

Child dose

The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age (see the “Other” section).

This medication prevents blood from clotting to avoid thrombus formation. However, it may increase the risk of bleeding, so it should not be used in patients with pathologically active bleeding or a history of intracranial hemorrhage. Patients scheduled for surgery should discontinue this medication at least 5 days prior to the procedure, and any signs of bleeding should be reported to the healthcare provider immediately. Patients with hypersensitivity to this medication or severe liver impairment, as well as those taking certain potent drugs, should avoid it due to the increased risk of side effects. Caution should be exercised in patients at high risk of bleeding or those who have recently undergone surgery, especially when taken with other drugs affecting blood coagulation. Symptoms such as bradycardia or respiratory distress may occur, and patients experiencing these symptoms should consult their healthcare provider. Women who are pregnant or breastfeeding should discuss their plans for pregnancy while taking this medication and may need to discontinue breastfeeding if necessary. This medication is not recommended for patients under 18 years of age as its safety and efficacy have not been established in this population. Overdosage may further increase the risk of bleeding, so adherence to dosage is critical, and any unusual symptoms should be reported to the healthcare provider immediately. While taking this medication, patients should be vigilant about signs of bleeding, respiratory distress, dizziness, and should exercise caution while driving or operating machinery.

• Bleeding
• intracranial hemorrhage
• ocular bleeding
• ear bleeding
• hypotension
• respiratory distress
• respiratory tract bleeding
• gastrointestinal bleeding
• diarrhea
• nausea

This medication may be sensitive to air and moisture, so it should be stored in a tightly sealed container. It is best stored at room temperature between 1 to 30 degrees Celsius. Proper storage will help maintain the effectiveness of the medication safely.

Appearance

Pink, double convex, round film-coated tablet

Package unit

56 tablets (14 tablets PTP x 4)